Skip to main content
Journal ArticleOPEN ACCESS

CTLA-4 Blockade Resistance after Relatlimab and Nivolumab

  • Menzies A
  • Pires da Silva I
  • Trojaniello C
  • et al.
New England Journal of Medicine (2022) 386(17) 1668-1669
DOI: 10.1056/nejmc2119768
19Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.

Abstract

Ipilimumab after Anti–PD-1 and Anti–LAG-3 Therapy Data were pooled from 36 patients who received the anti–CTLA-4 antibody ipilimumab after metastatic melanoma progression during therapy with nivolu...

Cite

CITATION STYLE

APA

Menzies, A. M., Pires da Silva, I., Trojaniello, C., Vieu, E., Amaria, R. N., Zimmer, L., … Long, G. V. (2022). CTLA-4 Blockade Resistance after Relatlimab and Nivolumab. New England Journal of Medicine, 386(17), 1668–1669. https://doi.org/10.1056/nejmc2119768

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free